home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550870.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
33 lines
Document 0870
DOCN M9550870
TI Clinical aspects of human immunodeficiency virus disease: clinical
rationale for treatment.
DT 9505
AU Murphy R; Division of Infectious Diseases, Northwestern University
School; of Medicine, Chicago, Illinois.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S81-7. Unique Identifier : AIDSLINE
MED/95164993
AB Guidelines regarding the use of antiretroviral therapy in adult patients
infected with human immunodeficiency virus have been based primarily on
the results of 15 major clinical trials in which patients have been
categorized according to CD4 cell counts, symptoms, prior therapy, and
conditions. In patients with limited treatment experience and advanced
disease, zidovudine monotherapy is associated with improved survival,
whereas only a transient delay in progression of disease is observed in
patients with > 200 CD4 cells/mm3. Adding zalcitabine to the treatment
regimen of zidovudine-experienced patients with advanced disease has not
been demonstrated to be of clinical benefit, whereas switching these
patients to didanosine may delay disease progression. The effect of any
antiretroviral therapy in zidovudine-experienced patients with < 50 CD4
cells/mm3 remains indeterminate. The perinatal transmission rate can be
reduced by as much as two-thirds when zidovudine is administered to
women after the first trimester.
DE Clinical Trials CD4 Lymphocyte Count Dideoxynucleosides/*THERAPEUTIC
USE Female Human HIV Infections/*DRUG THERAPY/IMMUNOLOGY Male
Pregnancy Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL
ARTICLE REVIEW REVIEW, TUTORIAL
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).